CagriSema
Also known as Semaglutide + Cagrilintide
Investigational combination therapy demonstrating 22.7% body weight reduction at 68 weeks in Phase 3 trials, outperforming semaglutide monotherapy.
Regulatory Pathway
Dosing Protocol
Typical Dose
Semaglutide 2.4mg + Cagrilintide 2.4mg weekly
Frequency
Weekly
Duration
Long-term use expected
Timing & Administration
Administer via Subcutaneous injection. Frequency: Weekly.
Popular Uses
Mechanism of Action
Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide) for enhanced satiety and gastric control through complementary pathways.
Research Summary
Evidence level: clinical trials. Clinical status: NDA Submitted - Expected approval late 2026/early 2027.
Side Effects & Safety
Important Warnings
- Higher gastrointestinal effects than semaglutide alone
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
View profile